RNAZ · Transcode Therapeutics, Inc. · Investor Relations
$1.70
+0.00 (+0.00%)
At close · Oct 19
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Due to the Company's recurring and expected continuing losses from operations, the Company has concluded there is substantial doubt concerning its ability to continue as a going concern for one year after the issuance of these consolidated financial statements without additional capital becoming available.”View the 10-Q filed Aug 14, 2026
Market Cap
$28.78M
Shares
16.93M
Volume · Oct 19
29.32K
Avg daily vol (3M)
53.32K
Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Upcoming events
| Date | Event | Type |
|---|---|---|
| 2026-11-09 00:00 UTC | BIO Europe | Event |
Past events
| Date | Event | Type |
|---|---|---|
| 2026-09-23 | RNA leaders | Event |
| 2026-09-17 | TransCode joins RedChip to discuss its growing oncology pipeline, including innovative RNA therapeutics, immuno-oncology programs, and cancer vaccines | Event |
| 2026-06-18 | TransCode's First Live Virtual R&D Webcast | Webcast |
| 2026-04-08 | Castle Delivery | Event |
| 2026-02-10 | Immuno-Oncology 360 | Event |
| 2025-12-09 | San Antonio Breast Cancer Symposium | Event |
| 2025-10-16 | European Society for Medical Oncology | Event |
| 2025-05-30 | ASCO Annual Meeting | Shareholder meeting |
| 2025-05-12 | Bio Equity | Event |
| 2025-03-24 | IO360 Summit | Event |